Interactive case-based learning in ADPKD
-
LEARNING OBJECTIVES
At the end of this program, participants will be able to:
- Evaluate risk progression in ADPKD
- Identify patients at high risk of progression
- Determine whether patients are suitable candidates for tolvaptan treatment
SECTION 3 CREDITS:
Speaking Volumes 3: Portraits of PKD has been approved by the Canadian Society of Nephrology and is an accredited Self-Assessment Program (Section 3), as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada. Devised to achieve scientific integrity, objectivity and balance, this program was made possible through an unrestricted educational grant from Otsuka Canada Pharmaceutical Inc. (OCPI).
To claim two (2) credits per hour of educational activity, you must complete the Self-Assessment Test, save your results and the Certificate of Completion, and enter this activity into MAINPORT (http://www.mainport.org).
DISCLAIMER
This educational program was developed and reviewed by a panel of ten (10) Canadian nephrologists with experience in diagnosing and managing autosomal dominant polycystic kidney disease (ADPKD), and who have used ADPKD-specific medication in clinical trials and in real life.
There were no evidence-based clinical practice guidelines for the diagnosis and management of ADPKD at the time this program was developed. The opinions expressed in this program are those of the program faculty at the time the program was developed, and are not to be considered as directive.
CONTENT DEVELOPMENT COMMITTEE
Philip McFarlane, MD, PhD, FRCP(C) - Chair
Clinical Investigator, Division of Nephrology, St. Michael's Hospital
Assistant Professor, University of Toronto
Toronto, OntarioAhsan Alam, MDCM, MS, FRCP(C)
Nephrologist, MUHC McGill, Glen Site
Associate Professor of Medicine, McGill University
Montreal, QuebecDaniel Bichet, MD
Nephrologist, Sacré-Cœur de Montréal Hospital
Professor of Medicine and Molecular & Integrative Physiology, University of Montreal
Montreal, QuebecLouis Girard, MD, MBT, FRCP(C)
Nephrologist, Division of Nephrology, University of Calgary
Clinical Assistant Professor, University of Calgary
Calgary, AlbertaYork Pei, MD, FRCP(C)
Nephrologist, Toronto General Hospital, University Health Network
Professor of Medicine, University of Toronto
Toronto, OntarioPaul René de Cotret, MD, FRCP(C), ABIM - Reviewer
Director, Division of Nephrology, Laval University
Professor of Medicine, Laval University
Quebec City, QuebecSteven D. Soroka, BMus, MD, MSc, FRCP(C), EXTRA Fellow, CHE
Nephrologist, Department of Medicine, Nova Scotia Health Authority
Medical Lead, Central Zone Renal Program, Nova Scotia Health Authority
Medical Lead, Pharmacy and Renal Program, Nova Scotia Health Authority
Professor of Medicine, Dalhousie University
Halifax, Nova ScotiaDr. Paul Tam, MD, FRCP(C), FACP
Nephrologist, The Scarborough Hospital
Medical Director, Scarborough Regional Nephrology Program
Scarborough, OntarioSheldon Tobe, MD, MScCH (HPTE), FRCP(C), FACP, FASH
Nephrologist and Hypertension Specialist, Sunnybrook Health Sciences Centre
HSF/NOSM Chair in Aboriginal and Rural Health Research
Professor of Medicine, University of Toronto Toronto, OntarioJordan Weinstein, MD, FRCP(C)
Nephrologist, St. Michael's Hospital
Assistant Professor of Medicine, University of Toronto
Toronto, Ontario -
CASE 1: David, a 31-year-old man with abnormal findings on abdominal ultrasound
Philip McFarlane, MD, PhD, FRCP(C) - Chair
Clinical Investigator, Division of Nephrology, St. Michael's Hospital
Assistant Professor, University of Toronto
Toronto, OntarioDr. Philip McFarlane is a clinical investigator in the Division of Nephrology and Chief Nephrologist in the Live Kidney Donor Program at St. Michael's Hospital in Toronto, as well as an Assistant Professor at the University of Toronto. He is a member of the Canadian Diabetes Association Clinical Practice Guidelines group, the Canadian Society of Nephrology guideline group and the Canadian Hypertension Education Program.
Dr. McFarlane completed his PhD in Health Economics at the institute for Medical Sciences at the University of Toronto, and his research interests include health economics and outcomes. He has published over 60 peer-reviewed manuscripts and three book chapters.
-
CASE 2: Mark, a 35-year-old man with severe hypertension
Ahsan Alam, MDCM, MS, FRCP(C)
Nephrologist, MUHC McGill, Glen Site
Associate Professor of Medicine, McGill University
Montreal, QuebecDr. Ahsan Alam is an Associate Professor of Medicine and Director of the Internal Medicine Residency Training Program at McGill University. He is also a staff nephrologist and member of the multi-organ transplant program at the Royal Victoria Hospital in Montreal.
Dr. Alam completed a master’s degree in clinical research at the Sackler School of Graduate Biomedical Sciences at Tufts University in Boston. He has participated in several ADPKD clinical trials, including the TEMPO 3/4 Study. He was a member of the KDIGO Controversies Conference on ADPKD and speaks at the American Society of Nephrology pre-course on ADPKD.
-
CASE 3: Jillian, a 20-year-old woman being assessed as a transplant donor for her aunt with ADPKD
Louis Girard, MD, MBT, FRCP(C)
Nephrologist, Division of Nephrology, University of Calgary
Clinical Assistant Professor, University of Calgary
Calgary, AlbertaDr. Louis Girard joined the Division of Nephrology of the University of Calgary in July 2010 as a nephrologist and Clinical Assistant Professor. Within the Division of Nephrology, Dr. Girard focuses on clinical immunology and infectious diseases in chronic kidney disease patients. He is the Medical Director of the Glomerulonephritis Clinic and the Medical Co-Director of Apheresis. Furthermore, he has developed a multi-disciplinary Tuberous Sclerosis clinic that operates out of the Southern Alberta Renal Program, and is currently developing a multi-disciplinary clinic for patients with ADPKD.
Dr. Girard has a strong clinical research interest. He is currently the local primary investigator on numerous global trials in glomerulonephritis and vasculitis. From an ADPKD perspective, he is a site primary investigator for the C-MAJOR registry and is currently a member of the Canadian Consensus Recommendation Committee.
Dr. Girard has a strong commitment to education and has won numerous awards for his teaching contributions at all levels of medical training.
Disclaimer
This program was made possible with the support of Otsuka Canada Pharmaceutical Inc. (“Sponsor”). The views expressed in this program do not necessarily reflect those of UKidney and the Sponsor. This program might include information about drugs or indications that have not been approved in Canada.